Lightricks’ LTX Studio, the AI Visual Storytelling Platform, Now Open to All
Lightricks, the AI innovators behind Facetune, Videoleap, Photoleap and Popular Pays, announced today that LTX Studio beta, the first AI-driven storyboarding and prototyping platform, is now open to the public. The platform, designed for creative film and marketing professionals, offers real-time, intuitive generative and editing solutions. This announcement includes new features that push the boundaries of visual storytelling, such as increased character and frame control and multi-user collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240820994937/en/
The LTX Studio platform integrates proprietary AI research from Lightricks engineers with the latest licensed and open-source generative AI models, redefining the creative process. It streamlines video production planning and execution, empowering a wide range of creative professionals—from individual filmmakers to large production companies and advertising agencies—to develop, visualize, storyboard, and pitch their creative concepts into fully crafted film and video projects with unprecedented efficiency and control.
“Releasing LTX Studio to everyone demonstrates our ongoing commitment to the future of video creation through innovative AI-driven tools and our belief in generative AI as a powerful market changer," said Zeev Farbman, CEO and co-founder of Lightricks. “We’ve worked closely with our design partners and creator community to ensure our platform meets their diverse needs better than anything else on the market. We remain committed to exploring new technology and enhancing LTX Studio’s capabilities.”
LTX Studio’s suite of AI features has been refined based on technical and creative feedback from our creative community of more than 35,000 members. The latest updates focus on:
- Enhanced Collaboration: The new Collaboration feature enables creative teams to work together more efficiently with live edit views. LTX Studio plans to release additional collaborative tools, such as commenting and suggestion capabilities, soon.
- Character Acting: LTX Studio now syncs realistic voices with lip movements for any character, allowing users to customize facial gestures and dialogues by referencing real human videos. Users can generate voice from text using AI or upload their original voice files. Future updates will include voice switching for character dialogue and complete scene editing with dialogues.
- Generation Control: Users can now enjoy more control and accuracy in creating their wanted frames and desired motion. Frame Creator lets users craft frames using prompts and scribbles. Keyframe Control generates frames between defined start and end points.
Case Study: Recently, financial services company eToro used LTX Studio to create an AI-generated advertisement that aired during the Paris Olympics. This showcased LTX Studio’s ability to produce high-quality, realistic video content, demonstrating how brands can easily leverage LTX Studio to create compelling visual stories.
Pricing: LTX Studio now offers a tiered pricing model. Users can experience the platform for free with limited generative AI capability, or select from a range of plans based on their monthly generative time needs. Custom plans with premium features are available for enterprises and larger organizations and teams.
Lightricks is embarking on a prolific roadmap for LTX Studio leading into 2025, focusing on leveraging AI to innovate the visual storytelling experience and fuel creativity for professional creators globally. To experience LTX Studio today, join at LTX.Studio.
About Lightricks
Lightricks, an AI-first company, is revolutionizing how visual content is created. With a mission to bridge the gap between imagination and creation, Lightricks is dedicated to bringing cutting-edge technology to the creative and business spaces.
Our AI photo and video generation models, which power our apps and platforms including Facetune, Photoleap, Videoleap, and LTX Studio, allow creators and brands to leverage the latest research breakthroughs, offering endless control over their creative potential. Our influencer marketing platform, Popular Pays, provides creators the ability to monetize their work and offers brands opportunities to scale their content through tailored creator partnerships.
Founded in 2013, Lightricks is backed by prominent investors including Goldman Sachs Growth Equity, Insight Partners and Viola Ventures, who share Lightricks’ enduring commitment to driving the future of content creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820994937/en/
Contacts
Olivia Knecht
lightricks@clarity.global
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom